The Burnham Institute last week announced that Douglas Obenshain has been elected to its board of trustees. Obenshain is a partner with Ernst & Young, where his practice focuses primarily on biotechnology, pharmaceutical, and medical device companies, the institute said.
Elliott Sigal has been named acting president of the Bristol-Myers Squibb Pharmaceutical Research Institute, BMS said last week. He covers for James Palmer, the current president, who recently underwent surgery. Sigal is senior vice president for global clinical and pharmaceutical development at Bristol-Myers Squibb.
David Schwartz will be the new director of the National Institute of Environmental Health Sciences and the National Toxicology Program, the NIH said last week. He will replace Kenneth Olden, who stepped down as NIEHS director last year, and will begin his appointment on April 4. Schwartz is currently the director of the pulmonary, allergy, and critical care division and vice chair of research in the department of medicine at Duke University. He holds an MD from the University of California San Diego, an MPH from Harvard School of Public Health, and a BA in biology from the University of Rochester.
Manuel Hidalgo has joined the scientific advisory board of Aclara BioSciences, the company said last week.
Hidalgo is an associate professor of oncology and co-director of the drug development program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Hidalgo received an MD from the University Navarra Medical School in Pamplona, Spain, and a PhD in infectious disease from the University of Autonoma in Madrid.